[go: up one dir, main page]

MX2023010661A - Moléculas de union al receptor leucocitario humano similar a inmunoglobulina b1 (lilrb1) y al receptor leucocitario humano similar a inmunoglobulina b2 (lilrb2) y usos para las mismas. - Google Patents

Moléculas de union al receptor leucocitario humano similar a inmunoglobulina b1 (lilrb1) y al receptor leucocitario humano similar a inmunoglobulina b2 (lilrb2) y usos para las mismas.

Info

Publication number
MX2023010661A
MX2023010661A MX2023010661A MX2023010661A MX2023010661A MX 2023010661 A MX2023010661 A MX 2023010661A MX 2023010661 A MX2023010661 A MX 2023010661A MX 2023010661 A MX2023010661 A MX 2023010661A MX 2023010661 A MX2023010661 A MX 2023010661A
Authority
MX
Mexico
Prior art keywords
lilrb1
lilrb2
binding molecules
uses therefor
antibodies
Prior art date
Application number
MX2023010661A
Other languages
English (en)
Inventor
Jacqueline M Mason
Richard Brokx
Mark Robert Bray
Gordon S Duncan
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of MX2023010661A publication Critical patent/MX2023010661A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Vending Machines For Individual Products (AREA)
  • Carbon And Carbon Compounds (AREA)

Abstract

La invención proporciona nuevos anticuerpos anti-LILR, composiciones farmacéuticas que comprenden los anticuerpos y métodos terapéuticos para usar los anticuerpos y composiciones farmacéuticas para el tratamiento de enfermedades tales como cáncer, enfermedades autoinmunitarias o inflamación alérgica.
MX2023010661A 2021-03-11 2022-03-11 Moléculas de union al receptor leucocitario humano similar a inmunoglobulina b1 (lilrb1) y al receptor leucocitario humano similar a inmunoglobulina b2 (lilrb2) y usos para las mismas. MX2023010661A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163159613P 2021-03-11 2021-03-11
PCT/CA2022/050363 WO2022187968A1 (en) 2021-03-11 2022-03-11 Lilrb1 and lilrb2-binding molecules and uses therefor

Publications (1)

Publication Number Publication Date
MX2023010661A true MX2023010661A (es) 2023-11-28

Family

ID=83226145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010661A MX2023010661A (es) 2021-03-11 2022-03-11 Moléculas de union al receptor leucocitario humano similar a inmunoglobulina b1 (lilrb1) y al receptor leucocitario humano similar a inmunoglobulina b2 (lilrb2) y usos para las mismas.

Country Status (12)

Country Link
US (1) US20240150462A1 (es)
EP (1) EP4305068A1 (es)
JP (1) JP2024512422A (es)
KR (1) KR20230156384A (es)
CN (1) CN117321083A (es)
AU (1) AU2022233201A1 (es)
BR (1) BR112023018378A2 (es)
CA (1) CA3211777A1 (es)
IL (1) IL305794A (es)
MX (1) MX2023010661A (es)
TW (1) TW202246342A (es)
WO (1) WO2022187968A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4188430A4 (en) * 2020-07-28 2024-11-06 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use
WO2024238639A2 (en) * 2023-05-17 2024-11-21 The Administrators Of The Tulane Educational Fund Antigens for seroprevalence, anti-glucanase antibodies and diagnostics of pneumocystis pneumonia
WO2024260384A1 (en) * 2023-06-20 2024-12-26 Elpiscience (Suzhou) Biopharma, Ltd. Antibodies or antigen-binding fragments binding to lilrb1 and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12157768B2 (en) * 2018-09-17 2024-12-03 Icahn School Of Medicine At Mount Sinai Anti-LILRB2 antibodies and methods of use thereof
US20220025045A1 (en) * 2018-12-26 2022-01-27 Innate Pharma Compounds and methods for treatment of head and neck cancer
CA3150428A1 (en) * 2019-08-12 2021-02-18 Biond Biologics Ltd. Antibodies against ilt2 and use thereof

Also Published As

Publication number Publication date
EP4305068A1 (en) 2024-01-17
WO2022187968A1 (en) 2022-09-15
CN117321083A (zh) 2023-12-29
AU2022233201A1 (en) 2023-09-28
CA3211777A1 (en) 2022-09-15
BR112023018378A2 (pt) 2023-12-05
IL305794A (en) 2023-11-01
US20240150462A1 (en) 2024-05-09
TW202246342A (zh) 2022-12-01
JP2024512422A (ja) 2024-03-19
KR20230156384A (ko) 2023-11-14

Similar Documents

Publication Publication Date Title
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2023010661A (es) Moléculas de union al receptor leucocitario humano similar a inmunoglobulina b1 (lilrb1) y al receptor leucocitario humano similar a inmunoglobulina b2 (lilrb2) y usos para las mismas.
PH12022500003A1 (en) Il-2 conjugates and methods of use to treat autoimmune diseases
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
ZA202202363B (en) Antibodies against ilt2 and use thereof
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
MX2024005705A (es) Composiciones de liquidos ionicos.
SA523440623B1 (ar) أجسام مضادة
MX2023004032A (es) Terapias inmuno-oncologicas con conjugados de il-2.
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
MX2021008507A (es) Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas.
MX2021015974A (es) Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados.
AU2018320418A1 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
EA202092518A1 (ru) Композиции и способы лечения рака
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
BR112023002455A2 (pt) Anticorpos fgfr3 e métodos de uso
MX2023012672A (es) Nuevo anticuerpo anti-vista estable.
NZ778810A (en) Antibodies targeting c5ar
WO2021191689A3 (en) Treatment of inflammatory diseases with peptides and pharmaceutical compositions
AU2018320416A8 (en) Pyridylpyridone compounds
WO2019160806A3 (en) Novel crystalline forms of tamibarotene for treatment of cancer
WO2020186111A3 (en) Vista-binding antibodies and uses thereof